	Application No.	Applicant(s)
Notice of Allowability	10/025,936	BRIESEWITZ ET AL.
	Examiner	Art Unit
	David M. Naff	1651
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSED in or other appropriate common GHTS. This application is 1	n this application. If not included unication will be mailed in due course. <b>THIS</b>
1. 🛮 This communication is responsive to amendment of 11/26/	<u>03</u> .	
2. X The allowed claim(s) is/are 23-29,31,32,35-44,49,50,52 an	<del></del>	
3. The drawings filed on are accepted by the Examine	·.	
4. Acknowledgment is made of a claim for foreign priority ur	der 35 U.S.C. § 119(a)-(d)	or (f).
a) All b) Some* c) None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet, 37 CFR 1.78.		
(a) The translation of the foreign language provisional application has been received.		
6. Acknowledgment is made of a claim for domestic priority ur in the first sentence of the specification or in an Application	der 35 U.S.C. §§ 120 and/d	or 121 since a specific reference was included
Applicant has THREE MONTHS FROM THE "MAILING DATE" of below. Failure to timely comply will result in ABANDONMENT of the complete of the comple	this communication to file a	reply complying with the requirements noted
7. A SUBSTITUTE OATH OR DECLARATION must be submi		
8. ☐ CORRECTED DRAWINGS ( as "replacement sheets") mus  (a) ☐ including changes required by the Notice of Draftspers  1) ☐ hereto or 2) ☐ to Paper No		v ( PTO-948) attached
(b) ☐ including changes required by the proposed drawing or	orrection filed, which	h has been approved by the Examiner.
(c) ☐ including changes required by the attached Examiner's	Amendment / Comment or	in the Office action of Paper No
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the		
DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT FOR TI		
Attachment(s)		
1☐ Notice of References Cited (PTO-892)	5 ☐ Notice of Info	ormal Patent Application (PTO-152)
2☐ Notice of Draftperson's Patent Drawing Review (PTO-948)		mmary (PTO-413), Paper No. <u>12/18/03</u> .
3 Information Disclosure Statements (PTO-1449 or PTO/SB/08) Paper No	7⊠ Examiner's A	mendment/Comment
4 Examiner's Comment Regarding Requirement for Deposit of Biological Material	8☐ Examiner's S 9☐ Other	statement of Reasons for Allowance

David M. Naff Primary Examiner Art Unit: 1651 Application/Control Number: 10/025,936

Art Unit: 1651

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

In the specification, first page, line 17, after "1999"
insert --- , now U.S. Patent No. 6,372,712 B1, ---.

Applicants' representative, Bret E. Field, authorized the following amendments by telephone on 12/18/03:

Title, cancel the title and insert the following title --ADMINISTERING BIFUNCTIONAL MOLECULES CONTAINING A DRUG MOIETY
AND PRESENTER PROTEIN LIGAND FOR THERAPY ---.

In the abstract (amendment of 11/26/03),

lines 4 and 9, cancel "subject",

line 6, after "protein" insert --- and ---.

In the claims,

claim 35,

line 1, cancel "a", second occurrence (at the end of the line), and insert --- an intracellular drug ---;

line 2, after "cell", second occurrence, insert --containing the drug target ---;

line 4, after "protein" insert --- that is not said drug target ---;

173

Application/Control Number: 10/025,936
Art Unit: 1651

line 5, cancel "a" and insert --- the ---;

line 6, after "target", first occurrence, insert --- in said first cell ---, change "a" to --- the ---, and cancel "that is not said drug target" and insert --- in said second cell ---;

line 8, cancel "but not said first cell" and insert --wherein the drug does not bind to the drug target in the second
cell, and to produce a binary complex comprising said
bifunctional molecule and drug target in said first cell wherein
the drug binds to the drug target in the first cell ---

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David M. Naff whose telephone number is 703-308-0520. The examiner can normally be reached on Monday-Friday 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 703-308-4743. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.



Application/Control Number: 10/025,936

Art Unit: 1651

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

David M. Naff Primary Examiner Art Unit 1651 Page 4

DMN 12/18/03